Literature DB >> 19843401

Histamine, antihistamines, and the central nervous system.

Philip Lieberman1.   

Abstract

Histamine is a central nervous system (CNS) neurotransmitter. It acts in the brain via three receptors, H(1), H(2), and H(3). It is a mediator of "wakefulness" and its activity is necessary to maintain wakefulness, alertness, and reaction time. These activities can be impaired by H(1)-antagonists (reverse agonists) capable of penetrating the blood-brain barrier. By blocking the homeostatic effects of histamine in the CNS, drowsiness and functional impairment with or without drowsiness can occur. Several tests have been designed to assess the effects of antihistamines on the CNS. These include subjective measurements of drowsiness and more objective measurements of impairment. Second-generation antihistamines have been designed to minimize blood-brain barrier penetration by reducing lipophilicity and increasing the affinity for P-aminnoglycoprotein.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843401     DOI: 10.2500/aap.2009.30.3264

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  10 in total

1.  Overdose of the histamine H₃ inverse agonist pitolisant increases thermal pain thresholds.

Authors:  Dong Dong Zhang; Marco Sisignano; Claus Dieter Schuh; Kerstin Sander; Holger Stark; Klaus Scholich
Journal:  Inflamm Res       Date:  2012-07-21       Impact factor: 4.575

Review 2.  Bilastine: in allergic rhinitis and urticaria.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

Review 3.  Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions.

Authors:  Amalia Leceta; Aintzane García; Ander Sologuren; Cristina Campo
Journal:  Drugs Context       Date:  2021-08-10

4.  Histamine H3 Inverse Agonist BF 2649 or Antagonist with Partial H4 Agonist Activity Clobenpropit Reduces Amyloid Beta Peptide-Induced Brain Pathology in Alzheimer's Disease.

Authors:  Ranjana Patnaik; Aruna Sharma; Stephen D Skaper; Dafin F Muresanu; José Vicente Lafuente; Rudy J Castellani; Ala Nozari; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

5.  Chronic pelvic allodynia is mediated by CCL2 through mast cells in an experimental autoimmune cystitis model.

Authors:  Fuat Bicer; Cengiz Z Altuntas; Kenan Izgi; Ahmet Ozer; Michael Kavran; Vincent K Tuohy; Firouz Daneshgari
Journal:  Am J Physiol Renal Physiol       Date:  2014-09-10

Review 6.  Interactions of the histamine and hypocretin systems in CNS disorders.

Authors:  Ling Shan; Yves Dauvilliers; Jerome M Siegel
Journal:  Nat Rev Neurol       Date:  2015-06-23       Impact factor: 42.937

Review 7.  AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

Authors:  Alexandre V Ivachtchenko; Yan Lavrovsky; Ilya Okun
Journal:  J Alzheimers Dis       Date:  2016-05-25       Impact factor: 4.472

8.  Effects of loratadine, a histamine H1 receptor antagonist, on the skeletal system of young male rats.

Authors:  Joanna Folwarczna; Natalia Konarek; Karolina Freier; Dawid Karbowniczek; Piotr Londzin; Aleksandra Janas
Journal:  Drug Des Devel Ther       Date:  2019-09-23       Impact factor: 4.162

9.  Potentiometric sensing of histamine using immobilized enzymes on layered double hydroxides.

Authors:  Slah Hidouri; Abdel Hamid Errachid; Joan Baussels; Yaroslav I Korpan; Oscar Ruiz-Sanchez; Zouhair M Baccar
Journal:  J Food Sci Technol       Date:  2020-09-28       Impact factor: 3.117

Review 10.  Changes in Histaminergic System in Neuropsychiatric Disorders and the Potential Treatment Consequences.

Authors:  Ling Shan; Dick F Swaab
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.